Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and GLP-1 analog administration in patients with type 2 diabetes mellitus

• Autors principals: Junichi Okada (Autor), Eijiro Yamada (Autor), Yawara Niijima (Autor), Shuichi Okada (Autor), Masanobu Yamada (Autor)
• Format: Llibre
• Publicat: BMC, 2019-11-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract We monitored serum amylase level in patients with type 2 diabetes mellitus (T2DM) prescribed either dipeptidyl peptidase-4 inhibitor or GLP-1 analog (GLP-1 group) as monotherapy. Patients were treated for a 36-month period. All subjects were non-smoker and did not take any alcoholic beverag...